Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Colostrinin Distribution in Poland

2 Jun 2009 12:50

RNS Number : 2090T
ReGen Therapeutics PLC
02 June 2009
 



2/06/2009 

For immediate release

AIM/PLUS: RGT

ReGen Signs Exclusive Distribution Agreement for Colostrinin™ in Poland

ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that it has today signed an agreement with Tagerr Polska* for the exclusive distribution and marketing of its nutritional supplement Colostrinin™ in Poland. This comes after a period of test - marketing by Tagerr during which Tagerr also satisfied all necessary regulatory requirements to import/distribute the product in Poland. To date Colostrinin™ is marketed in the US, Canada and Australia under the brand name CogniSure™ ** and in Cyprus under the brand name Cognase™ *** as a nutritional supplement to 'support healthy brain ageing and cognition in humans'.

Commenting on this agreement Percy Lomax, Chairman and Chief Executive Officer of ReGen said :

'Poland is the country where Colostrinin™ was first discovered and we know from various communications that there is significant knowledge of the product in Poland. Poland has a population of 38 million people and a Gross Domestic Product per Capita of $11,072. As such both Tagerr Polska and ourselves are optimistic that the volume of sales here should be significant.'

\* Tagerr Polska is an affliate of Tagerr a professional services and trading company established in Köln, Germany. In operation since 1995, Tagerr has enjoyed considerable successes in marketing and distributing consumer products, including food supplements, in central Europe and Germany. (www.cognisure.eu

**Colostrinin™ for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.metagenics.com).

*** Colostrinin™ is distributed in the Republic of Cyprus by Golgi Pharmaceuticals Ltd (www.healthybrainaging.com)

 

For further information:

Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920

Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396

Nick Bealer/David Scott Alexander David Tel No 020 7448 9820

Notes to Editors:

Colostrinin™ is derived from colostrum a mammal's first milk after birth and is produced in a production line in S Dakota, freeze dried in Oregon and tabletted at Metagenics Inc plant in California. Metagenics are the distributors in North America and Australia. If full production and sales were achieved on North American margins revenue to the Company would be $10 million before relatively low head office expenses. It would be possible, by spending around another $550,000 to bring production facilities up to a level to generate revenue of around $50 million.

Colostrinin™ has been available in the professional channel of the healthcare market in North America and Australia for over a year. Although achieving professional awareness and endorsement was a necessary first step, retail distribution, was always and remains our objective. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCCKBKQDBKDOAK
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.